Current Price and Market Context
As of 19 May 2026, Windlas Biotech’s share price closed at ₹777.30, marginally down by 0.39% from the previous close of ₹780.35. The stock traded within a range of ₹760.25 to ₹778.85 during the day, remaining well below its 52-week high of ₹1,095.00 but comfortably above the 52-week low of ₹699.35. This price action reflects a consolidation phase amid broader market volatility.
Technical Trend Overview
The overall technical trend for Windlas Biotech has shifted from bearish to mildly bearish, signalling a tentative improvement but still reflecting underlying caution. This subtle change is underscored by mixed signals from various technical indicators, which paint a picture of a stock in transition rather than one exhibiting clear directional conviction.
MACD Analysis
The Moving Average Convergence Divergence (MACD) indicator presents a dichotomy in timeframe perspectives. On the weekly chart, the MACD is mildly bullish, suggesting some upward momentum building in the short term. However, the monthly MACD remains mildly bearish, indicating that longer-term momentum has yet to confirm a sustained uptrend. This divergence implies that while short-term traders might find some buying interest, longer-term investors should remain cautious.
RSI and Momentum Indicators
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory. This lack of momentum confirmation suggests that the stock is neither overbought nor oversold, reinforcing the notion of a consolidation phase. Meanwhile, the Know Sure Thing (KST) indicator aligns with the MACD’s mixed signals, being mildly bullish on the weekly timeframe but mildly bearish on the monthly, further emphasising the stock’s indecisive momentum.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Bollinger Bands and Moving Averages
Bollinger Bands on both weekly and monthly charts remain bearish, indicating that the stock price is trading near the lower band and suggesting downward pressure or increased volatility. This bearish stance contrasts with the daily moving averages, which also signal a bearish trend. The daily moving averages’ alignment below the price confirms short-term weakness, implying that the stock has yet to establish a firm base for a sustained rally.
On-Balance Volume and Dow Theory
Volume-based indicators provide additional insight. The On-Balance Volume (OBV) shows no clear trend on the weekly chart but is mildly bearish on the monthly, hinting at subdued buying interest over the longer term. Dow Theory analysis reveals no definitive trend on either weekly or monthly timeframes, reinforcing the technical ambiguity surrounding Windlas Biotech’s price action.
Comparative Returns and Market Performance
When compared with the broader Sensex index, Windlas Biotech’s returns have been mixed. Over the past week, the stock declined by 2.82%, underperforming the Sensex’s 0.92% drop. The one-month return shows a sharper decline of 10.18% versus Sensex’s 4.05%. Year-to-date, Windlas Biotech has marginally outperformed the Sensex with a -2.23% return compared to the index’s -11.62%. However, over the last year, the stock has lagged significantly with an 18.71% loss against the Sensex’s 8.52% gain. Longer-term performance remains impressive, with a three-year return of 185.04% far exceeding the Sensex’s 22.60%, highlighting the stock’s strong historical growth despite recent volatility.
Mojo Score and Grade Update
MarketsMOJO’s latest assessment assigns Windlas Biotech a Mojo Score of 40.0 and a Mojo Grade of Sell, downgraded from Hold on 4 February 2026. This downgrade reflects the deteriorating technical and fundamental outlook, signalling caution for investors. The company’s small-cap market capitalisation further adds to the risk profile, as smaller companies tend to exhibit higher volatility and lower liquidity.
Why settle for Windlas Biotech Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Technical Outlook and Investor Implications
Windlas Biotech’s technical indicators collectively suggest a stock at a crossroads. The mildly bullish weekly MACD and KST hint at potential short-term recovery, but the prevailing bearish signals from Bollinger Bands, moving averages, and monthly momentum indicators caution against premature optimism. The absence of clear RSI signals and Dow Theory trends further complicates the outlook.
Investors should weigh these mixed signals carefully. Short-term traders might capitalise on the mild bullish momentum seen in weekly indicators, but longer-term investors should remain vigilant given the monthly bearish trends and recent downgrade in Mojo Grade. The stock’s historical outperformance over three years indicates underlying strength, but recent price weakness and technical deterioration warrant a cautious approach.
Conclusion
In summary, Windlas Biotech Ltd is navigating a complex technical environment marked by a shift from bearish to mildly bearish momentum. While some weekly indicators suggest nascent bullishness, the broader monthly and daily signals remain bearish, reflecting uncertainty and volatility. The recent downgrade to a Sell rating by MarketsMOJO underscores the need for prudence. Investors should monitor key technical levels and volume trends closely before committing to new positions, balancing the stock’s long-term growth potential against its current technical challenges.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
